Oxaliplatin Added to Simplified Bimonthly Low-Dose Leucovorin and 5-FU for Pretreated Advanced Colorectal Cancer Is Effective and Not Affected by Different Previous 5-FU Regimens

References

• Mani S., Graham M. A., Bregman D. B., Ivy P., Chaney S. G. Oxaliplatin: a review of evolving concepts. Cancer Investig. 2002; 20(2)246–263, [CSA]
   PubMed Web of Science ®Google Scholar
• Machover D., Diaz-Rubio E., De Gramont A., Schilf A., Gastiaburu J. J., Brienza S., Itzhaki M., Metzger G., N'Daw D., Vignoud J., Abad A., Francois E., Gamelin E., Marty M., Sastre J., Seitz J. F., Ychou M. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoro pyrimidines. Ann. Oncol. 1996; 7(1)95–98, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Louvet C., Andre T., Tournigand C., Krulik M. A review of GERCOD trials of bimonthly leukovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Eur. J. Cancer 1998; 34(5)619–626, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high leukovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997; 33(2)214–219, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Andre T., Louvet C., Raymond E., Tournigand C., de Gramont A. Bimonthly high-dose leukovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leukovorin and 5-fluorouracil regimen. Ann. Oncol. 1998; 9(11)1251–1253, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Andre T., Bensmaine M. A., Louvet C., Francois E., Lucas V., Desseigne F., Beerblock K., Bouche O., Carola E., Merrouche Y., Morvan F., Dupont-Andre G., de Gramont A. Multicenter phase II study of bimonthly high-dose leukovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer resistant to the same leukovorin and fluorouracil regimen. J. Clin. Oncol. 1999; 17(11)3560–3568, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz J. P., Molitor J. L., Garcia M. L., Gilles-Amar V., Izrael V., Krulik M., de Gramont A. Oxaliplatin added to the simplified bimonthly leukovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur. J. Cancer 1999; 35(9)1338–1342, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., de Gramont A., Louvet C., Andre T., Carola E., Gilles V., Lotz J. P., Tournigand C., Mabro M., Molitor J. L., Artru P., Izrael V., Krulik M. Evaluation of oxaliplatin dose-intensity with bimonthly leukovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann. Oncol. 2000; 11(11)1477–1483, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., de Gramont A., Louvet C., Andre T., Carola E., Mabro M., Artru P., Gilles V., Lotz J. P., Izrael V., Krulik M. High-dose intensity oxaliplatin added to the simplified bimonthly leukovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 2001; 37(8)1000–1005, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zori Comba A., Blajman C., Richardet E., Bella S., Vilanova M., Coppola F., Van Kooten M., Rodger J., Giglio R., Balbiani L., Perazzo F., Montiel M., Chacon M., Pujol F., Mickiewicz E., Cazap E., Recondo G., Lastiri F., Simon J., Wasserman E., Schmilovich A. A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur. J. Cancer 2001; 37(8)1006–1013, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yang T. S., Hsu K. C., Chiang J. M., Tang R., Chen J. S., Changchien C. R., Wang J. Y. A simplified regimen of weekly high dose 5-fluorouracil and leukovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. Cancer 1999; 85(9)1925–1930, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ardalan B., Chua L., Tian E. M., Reddy R., Sridhar K., Benedetto P., Richman S., Legaspi A., Waldman S., Morrell L. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leukovorin in colorectal cancer. J. Clin. Oncol. 1991; 9(4)625–630, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluouracil by leukovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J. Clin. Oncol. 1992; 10: 896–903
   PubMed Web of Science ®Google Scholar
• Leichman C. G., Fleming T. R., Muggia F. M., Tangen C. M., Ardalan B., Doroshow J. H., Meyers F. J., Holcombe R. F., Weiss G. R., Mangalik A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J. Clin. Oncol. 1995; 13(6)1303–1311, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hansen R. M., Ryan L., Anderson T., Krzywda B., Quebbeman E., Benson A., III, Haller D. G., Tormey D. C. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst. 1996; 88(10)668–674, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ychou M., Fabbro-Peray P., Perney P., Marcais O., Gouze C., Ribard D., Bons-Rosset F., Heran B., Veyrac M., Blanc F. A prospective randomized study comparing high- and low-dose leukovorin combined with same-dose 5-fluorouracil an advanced colorectal cancer. Am. J. Clin. Oncol. 1998; 21(3)233–236, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beerblock K., Rinaldi Y., Andre T., Louvet C., Raymond E., Tournigand C., Carola E., Favre R., de Gramont A. Bimonthly high-dose leukovorin and 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer. Cancer 1997; 79(6)1100–1105, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. E., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989; 7(10)1407–1418, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Bosset J. F., Milan C., Rougier P., Bouche O., Etienne P. L., Morvan F., Louvet C., Guillot T., Francois E., Bedenne L. A randomized trial comparing monthly low-dose leukovorin-5-fluorouracil bolus with bimonthly high-dose leukovorin-5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J. Clin. Oncol. 1997; 15(2)808–815, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yeh K. H., Cheng A. L. High-dose 5-fluorouracil infusional therapy is associated with hyperammonnaemia, lactic acidosis and encephalopathy. Br. J. Cancer 1997; 75(3)464–465, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Holen K. D., Saltz L. B. New therapies, new direction: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol. 2001; 2(5)290–297, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N., Elfring G. L., Miller L. L. Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000; 343(13)905–914, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gilles-Amar V., Garcia M. L., Sebille A., Maindrault-Goebel F., Louvet C., Beerblock K., Krulik M., De Gramont A. Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48 h leukovorin and 5 fluorouracil regimen (FOLFOX) in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 246a
   Google Scholar